Bristol-Myers Squibb

22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.

Be Biopharma, Inc. is a biopharmaceutical company focused on developing therapeutics derived from engineered B-cells in the immune system. Founded in 2020 and based in Cambridge, Massachusetts, Be Biopharma aims to address the limitations of existing cell and gene therapies, such as the need for chemotherapy prior to treatment and the challenges of providing multiple doses. The company employs precision genome editing to create durable and effective cell therapies, targeting a range of diseases, including cancer, autoimmune disorders, and infectious diseases. By enhancing the functionality of B-cell medicines, Be Biopharma seeks to improve treatment outcomes for conditions like Hemophilia B and other serious health issues.

Light Horse Therapeutics is a biotechnology company specializing in the application of gene editing to small-molecule drug discovery. It develops innovative methods to target the root causes of severe and life-threatening diseases, with an initial focus on challenging oncology targets. The company's advanced platform identifies critical functional domains within disease-related proteins, enabling the development of more effective therapies.

Bridgeway is an NJ State licensed nonprofit organization providing services to youth and adults experiencing mental health conditions.

Be Biopharma, Inc. is a biopharmaceutical company focused on developing therapeutics derived from engineered B-cells in the immune system. Founded in 2020 and based in Cambridge, Massachusetts, Be Biopharma aims to address the limitations of existing cell and gene therapies, such as the need for chemotherapy prior to treatment and the challenges of providing multiple doses. The company employs precision genome editing to create durable and effective cell therapies, targeting a range of diseases, including cancer, autoimmune disorders, and infectious diseases. By enhancing the functionality of B-cell medicines, Be Biopharma seeks to improve treatment outcomes for conditions like Hemophilia B and other serious health issues.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Aktis Oncology is a biotechnology company focused on the discovery and development of a new class of targeted radiopharmaceuticals aimed at treating various solid tumor cancers. The company has developed proprietary platforms to create tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered for high tumor penetration and prolonged residence time, allowing for effective tumor elimination while reducing the side effects typically associated with cancer treatments. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing treatment precision and efficacy.

Abata Therapeutics is a biotechnology company dedicated to developing innovative cell therapies for patients suffering from progressive multiple sclerosis and other severe autoimmune and inflammatory diseases. The company specializes in the manipulation of regulatory T cells (Tregs) to address these conditions, aiming to restore balance within the immune system. By engineering Tregs to precisely target disease-related antigens, Abata Therapeutics creates therapies that can effectively treat diseases such as multiple sclerosis and type 1 diabetes without imposing systemic immune suppression. Founded by experts in immunology and cell therapy, Abata is committed to translating advanced scientific research into meaningful therapies that improve the lives of individuals facing chronic autoimmune challenges.

Roswell Park Cancer Institute (RPCI), established in 1898 by Dr. Roswell Park, is recognized as America's first cancer center. It pioneered a multidisciplinary approach to cancer treatment, emphasizing collaboration between scientists and clinicians, which has become the benchmark for modern comprehensive cancer centers. RPCI is one of the few facilities in upstate New York designated as a "comprehensive cancer center" by the National Cancer Institute and is a member of the National Comprehensive Cancer Network (NCCN). Faculty at RPCI are actively involved in developing Clinical Practice Guidelines in Oncology™, which are the internationally recognized standards for oncology clinical policy and are continually updated to reflect the latest advancements in cancer treatment.

Envisagenics, Inc. is a bioinformatics company founded in 2013 and headquartered in Huntington, New York. The company specializes in RNA therapeutics and aims to simplify complex biomedical data to expedite the development of innovative therapeutic solutions. Envisagenics leverages its advanced analytics platform, SpliceCore, which utilizes artificial intelligence and machine learning to analyze RNA sequencing data. This cloud-based platform enables researchers to identify splicing errors linked to various diseases, including genetic disorders and cancers, and to discover potential drug targets and biomarkers. By streamlining the drug discovery process through computational simulations, Envisagenics significantly reduces the time, cost, and risks associated with drug development, thereby facilitating partnerships with biopharmaceutical companies to advance RNA-based therapies.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

Pathios Therapeutics is an early-stage biotech company based in Oxford, United Kingdom, focused on developing therapies for autoimmune diseases and cancer. Founded in 2017, the company specializes in creating small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to counteract the immunosuppressive effects of immune cells, such as tumor-associated macrophages, which are influenced by the acidic environment often found in tumors. By leveraging a deep scientific approach and human genetic insights, Pathios Therapeutics aims to generate novel therapeutics for advanced solid tumors and other unmet medical needs.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Nabla Bio is a biotechnology company that specializes in the development of an autoreverse platform for the discovery of innovative protein variants. These proteins, which exhibit unique qualities, are engineered to create new medicines and enhance nutritional products. By leveraging insights gained from billions of natural proteins, Nabla Bio enhances these variants through extensive experimentation, allowing for advanced applications in both medical and industrial fields. The company's focus on complex measurements of protein function positions it as a leader in the pursuit of previously unattainable protein capabilities.

The Patients Association is a non-profit organization. The organization provides medical, health, and social care services through a helpline, charity, and care home. Their customers' enquiries are addressed through phone, email, and online application.

Instituto Oncoguia is a non-governmental organization and an interactive information portal dedicated to improving the quality of life for cancer patients, their families, and the general public. The organization provides educational content about various types of cancer, their symptoms, and treatments. It also offers guidance and support to people living with cancer, helping them navigate their journey. The information provided by Instituto Oncoguia is strictly educational and is not intended to replace medical consultation, tests, or treatment. The organization was established following the creation of the Oncoguia portal in 2003, in response to the clinical observation of the psychological needs of cancer patients.

Blood Cancer UK is a community dedicated to beating blood cancer by funding research and supporting those affected.

FED is a non-profit organization that provides education, health, and migrant development services for the community.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Attralus, Inc. is a biopharmaceutical company dedicated to addressing the systemic nature of amyloidosis and enhancing the quality of life for affected patients. Incorporated in 2010 and headquartered in South San Francisco, California, Attralus develops proprietary peptide-based pan-amyloid targeting agents aimed at diagnosing and treating various forms and stages of systemic amyloidosis. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic use; and AT-03, an Fc-fusion protein designed for therapeutic applications. By targeting the common pathology present in all systemic amyloidosis diseases, Attralus seeks to create effective treatments for all subtypes, particularly those that currently lack available treatment options. The company was previously known as Aurora Bio, Inc., before rebranding in August 2020.

Cour Pharmaceuticals Development Co Inc, founded in 2012 and based in Elmhurst, Illinois, operates in the pharmaceutical sector with a focus on developing an immune-modifying platform. This platform aims to achieve antigen-specific tolerance for immune-mediated diseases and provides non-biological therapeutics for conditions such as acute inflammation, autoimmunity, and allergies. The company is engaged in the pharmaceutical development of products related to immunology, pathology, and cardiovascular health, enabling the treatment of various conditions, including encephalitis syndromes, autoimmune disorders, infections, and heart attacks.

Ratio Therapeutics is a pharmaceutical company focused on developing radiotherapeutics for cancer treatment. The company utilizes two research and development platforms, Trillium and Macropa, which facilitate the imaging, discovery, and advancement of novel radiopharmaceuticals. These platforms enable doctors to detect various epithelial-derived cancers, including breast, pancreatic, lung, and colon cancers, thereby aiding in timely and appropriate treatments.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics that target significant unmet medical needs in inflammatory and autoimmune diseases, as well as in immune-oncology. The company has established a proprietary platform that enables the creation of first-in-class biologics by assembling customized and highly homogeneous human glycans onto glycoproteins in a site-specific manner. This approach facilitates a deeper understanding of the role of glycans in human health and disease, positioning GlycoEra to contribute meaningfully to the advancement of novel treatment options in the healthcare sector.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that specializes in developing innovative therapies for neuropsychiatric disorders and pain management. The company is advancing its lead product candidate, KarXT, an oral modulator that has completed a Phase II clinical trial for acute psychosis in schizophrenia and is undergoing Phase Ib trials for various central nervous system disorders, including the cognitive and negative symptoms associated with schizophrenia, Alzheimer's disease, and dementia-related psychosis. Karuna Therapeutics is also actively developing a pipeline of muscarinic-targeted drug candidates to address unmet medical needs in these challenging areas. Founded in 2009, the company has established partnerships and licensing agreements to support its drug discovery efforts and to enhance its research capabilities.

Health Coalition of Passaic County provides data connectivity, analytics and reporting, community unification, and health care services.

Mirati Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, dedicated to developing innovative therapies for cancer patients. The company focuses on targeting the genetic and immunological drivers of cancer, with key product candidates including MRTX849, a KRAS G12C inhibitor currently in Phase I/II trials for various cancers such as non-small cell lung, colorectal, and pancreatic cancer. Additionally, Mirati is advancing sitravatinib, a spectrum-selective kinase inhibitor, which is undergoing Phase II trials for non-small cell lung cancer, alongside a preclinical program for a KRAS G12D inhibitor. The company has established collaborations with BeiGene, Ltd. for the development and commercialization of sitravatinib and with Novartis Pharmaceuticals Corporation for clinical research endeavors. Founded in 1995, Mirati Therapeutics continues to focus on addressing unmet medical needs in oncology.

AstronauTx is a biotechnology company focused on developing innovative treatments for Alzheimer's disease and other neurodegenerative conditions. The company specializes in restoring the normal function of astrocytes, which are crucial for supporting neuronal activity and maintaining brain health. In healthy individuals, astrocytes play a vital role in metabolism and the integrity of the blood-brain barrier; however, in neurodegenerative diseases, their dysfunction can contribute to neurotoxicity. By targeting these processes, AstronauTx aims to enable healthcare professionals to more effectively address the challenges posed by dementias, ultimately improving patient outcomes.

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.

Drexel University, established in 1891, is a comprehensive, globally recognized research university based in Philadelphia, Pennsylvania. With approximately 26,000 students, it is one of America's 15 largest private universities. Drexel is renowned for its leadership in experiential learning, academic technology, and use-inspired research. The university manages an endowment fund, overseen by the investment office, which supports scholarships, financial aid, university operations, staff support, basic research, and academics. The investment office manages the endowment's financial assets, guided by the university's board of trustees and assisted by the investment committee.

Cellares Corporation, founded in 2019 and based in South San Francisco, California, specializes in the development of cell therapies for cancer treatment. The company addresses significant manufacturing challenges associated with these therapies, which are often produced on a per-patient basis, leading to high costs and limited availability. Cellares is pioneering the Cell Shuttle, an automated, closed end-to-end manufacturing solution designed to enhance the scalability and efficiency of cell therapy production. This innovative system allows for the simultaneous production of ten times more patient doses compared to traditional manual methods, while also reducing process failure rates by three-fold and lowering manufacturing costs by up to 70 percent. By providing flexible and scalable manufacturing options, Cellares aims to accelerate the delivery of life-saving therapies to patients in need and support the broader biopharmaceutical industry in meeting global demand for these treatments.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

K36 Therapeutics is a biotechnology company focused on developing small molecule therapeutics for cancer treatment. The company specializes in translating epigenetic modulation of oncogenic pathways into effective therapies. By leveraging advanced technology, K36 Therapeutics creates orally bioavailable small molecules and selective inhibitors, aiming to enhance the treatment options available to healthcare professionals and improve outcomes for cancer patients.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, antibody-based therapies aimed at enhancing the lives of cancer patients. The company specializes in antibody-drug conjugates and other biologics, focusing on oncologic diseases with significant unmet medical needs. TORL BioTherapeutics employs a strategy that involves target identification and early discovery work, allowing them to selectively advance drug programs through novel licensing agreements. This approach enables their researchers to develop proprietary drugs with unique and optimized profiles, contributing to the advancement of cancer treatment options.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Penn Medicine Princeton Cancer Center provides access to the specialist clinical services, rehabilitative care, and support required during cancer treatment and recovery from cancer.

Mediar Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. It specializes in developing antibody-based therapeutics targeting key fibrotic mediator proteins involved in fibrosis, aiming to halt and potentially reverse this condition in chronically damaged organs. The company operates at the pre-clinical stage.

iVexSol Inc. is a biotechnology company based in Worcester, Massachusetts, specializing in the development of lentiviral vector (LVV) manufacturing technology. Established in 2018, the company addresses the critical shortage of LVVs, which serve as essential gene delivery vehicles in the production of cell and gene therapies (CGTs). iVexSol's innovative platform, known as Intelligent Vector Solutions, significantly enhances the scalability and cost-effectiveness of LVV production while reducing the complexity and development time associated with critical reagents. By employing banks of vector-producing cells, the technology allows for the generation of LVVs in higher quantities compared to traditional methods, thereby facilitating quicker scale-up and meeting global demand. This advancement not only shortens clinical development timelines but also aims to improve patient access to life-saving treatments for conditions such as later-stage cancers and various genetic disorders.

Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. It employs a combination of human genetics, functional genomics, and advanced microscopy techniques to identify novel targets and therapeutics. The company utilizes viral tools and platforms for screening targets that influence the progression of neurodegenerative conditions, alongside functional genetic screening and multi-omics methods. By integrating these state-of-the-art approaches, Cajal Neuroscience aims to advance precision medicine, ultimately enabling healthcare professionals to improve treatment outcomes for patients suffering from neurodegenerative disorders.

Kura Oncology is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing targeted therapies for cancer treatment. The company’s primary product candidate, Tipifarnib, is an orally available farnesyl transferase inhibitor currently undergoing Phase II clinical trials for solid tumors, peripheral T-cell lymphomas, and various hematologic malignancies. In addition to Tipifarnib, Kura is advancing other small molecule candidates, including KO-947, which targets dysregulated extracellular signal-related kinases, and KO-539, aimed at inhibiting the menin-mixed lineage leukemia protein interaction. Kura Oncology emphasizes precision medicine, leveraging insights from cancer genomics to create targeted treatments for patients with specific genetic profiles, addressing significant unmet medical needs across various cancer types, including lung, colorectal, thyroid, pancreatic cancers, and blood cancers such as lymphoma and leukemia. The company was founded in 2014 and operates primarily within the United States.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, founded in 2016. It operates a proprietary drug discovery platform that utilizes synthetic biology to expand the druggable proteome, focusing on therapeutic applications in oncology and rare diseases. The platform employs empirical intracellular selection to identify and design compounds that can modulate protein interactions, either disrupting specific protein-protein interactions or facilitating the targeted degradation of proteins through the recruitment of E3 ubiquitin ligases. SyntheX's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that evade chemotherapy through homologous recombination. The company identifies drug targets by analyzing clinical, evolutionary, phenotypic, and structural data, and it maintains both internal oncology projects and collaborative discovery initiatives.

Capstan Therapeutics is a biotechnology company focused on advancing precision in vivo cell engineering to create therapeutics for various disease categories that have unmet or underserved clinical needs. The company specializes in expanding the therapeutic potential of RNA-based therapies through proprietary targeted delivery systems. Their platform utilizes targeted lipid nanoparticles to enhance off-the-shelf immunotherapies, providing tight control over dosage and activity of engineered cells. This approach aims to develop transformative products for conditions such as oncology, fibrosis, and inflammation-related diseases.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Founded in 2017 and originally named Llama Therapeutics, the company aims to address significant unmet medical needs in neuropsychiatry, neurodegeneration, and neuroinflammation. Autobahn's lead candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential adjunctive treatment for multiple sclerosis, adrenomyeloneuropathy, major depressive disorder, and bipolar disorder depression. The company employs a brain-targeting chemistry platform that allows for precise tuning of CNS exposure while pursuing validated clinical and biological targets, guided by biomarkers, to unlock new therapeutic opportunities.

BigHat Biosciences, Inc. is a biotechnology company based in San Carlos, California, founded in 2019. The company specializes in developing an automated platform that combines a wet laboratory with artificial intelligence and machine learning techniques for the production and characterization of antibodies. This innovative platform empowers drug developers to engineer antibodies and other therapeutic proteins with improved biophysical properties and complex functions. By leveraging AI-guided design capabilities, BigHat aims to create safer and more effective treatments for patients facing challenging diseases, thereby advancing the field of biotherapeutics.

Owkin, Inc. is an artificial intelligence company that specializes in developing software aimed at improving treatment outcomes for patients, particularly in oncology. Established in 2016, with headquarters in New York and an office in Paris, Owkin employs AI tools to enhance drug discovery and accelerate clinical trials while safeguarding patient privacy through federated learning. The company offers several products, including Owkin Lab for therapeutic data connection, Owkin Loop for validated and packaged models, and a comprehensive software stack. Owkin's portfolio includes 30 live models, with an additional 40 in development, focusing on identifying new drug candidates and elucidating the mechanisms behind treatment efficacy. Co-founded by Thomas Clozel, a clinical research doctor, and Gilles Wainrib, a machine learning expert, Owkin has raised over $255 million and achieved unicorn status due to its innovative approach in addressing unmet medical needs and optimizing the drug development process.

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on designing and developing novel small molecule targeted therapies for oncology. The company specializes in creating next-generation tyrosine kinase inhibitors (TKIs) that address genetic drivers of cancer, catering to both TKI-naïve and TKI-pretreated patients. Its lead drug candidate, repotrectinib, is currently undergoing evaluation in the Phase I/II TRIDENT-1 trial for the treatment of patients with ROS1+ advanced non-small-cell lung cancer and those with ROS1+, NTRK+, or ALK+ advanced solid tumors. Additionally, Turning Point Therapeutics is advancing a pipeline that includes other multi-targeted drug candidates, such as TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. Founded in 2013, the company is dedicated to addressing the limitations of existing therapies through precision medicine in oncology.

Transition Bio, Inc. is a biotechnology company dedicated to advancing human health through the discovery, analysis, and modulation of biological condensates. Founded in 2020 and based in Cambridge, Massachusetts, with a branch in Cambridge, United Kingdom, the company has developed a hypothesis-free drug discovery and diagnostics platform known as Condensomics. This innovative platform leverages droplet microfluidic technologies and protein biophysics to study condensates with remarkable precision, providing medical practitioners with detailed molecular mappings. Transition Bio's approach is designed to unlock new opportunities for drug development, setting it apart in the biopharmaceutical landscape.

Sapience Therapeutics, Inc. is a biotechnology company focused on discovering and developing peptide-based therapeutics aimed at addressing high mortality cancers. Founded in 2015 and headquartered in Harrison, New York, the company is advancing novel therapies to meet significant unmet medical needs. Its lead product, ST101, is an inhibitor of the transcription factor C/EBPß, which is overexpressed in various cancers and plays a critical role in cellular differentiation, tumor survival, and proliferation. ST101 reduces the expression of several target genes and proteins associated with cancer cell survival and growth, inducing selective cytotoxicity in tumor types such as breast cancer, melanoma, prostate cancer, glioblastoma multiforme, lung cancer, and acute myeloid leukemia. The company aims to develop first-in-class treatments for deadly conditions, with a particular focus on glioblastoma, the most aggressive form of brain cancer.

Nuvig Therapeutics focuses on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function. The company is dedicated to creating a pipeline of novel immune therapeutics specifically targeting chronic inflammatory and autoimmune diseases. By harnessing natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options for patients, ultimately improving their health outcomes.

Octant Bio is a company focused on developing synthetic technology to enhance health and treat diseases. The firm employs synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells simultaneously. This approach allows scientists to use machine learning methods to engineer small molecules that can interact with multiple receptors, offering new potential for treating complex diseases.

Be Biopharma, Inc. is a biopharmaceutical company focused on developing therapeutics derived from engineered B-cells in the immune system. Founded in 2020 and based in Cambridge, Massachusetts, Be Biopharma aims to address the limitations of existing cell and gene therapies, such as the need for chemotherapy prior to treatment and the challenges of providing multiple doses. The company employs precision genome editing to create durable and effective cell therapies, targeting a range of diseases, including cancer, autoimmune disorders, and infectious diseases. By enhancing the functionality of B-cell medicines, Be Biopharma seeks to improve treatment outcomes for conditions like Hemophilia B and other serious health issues.

Ceptur Therapeutics is focused on developing innovative genetic medicines for patients with unmet medical needs. The company utilizes its proprietary U1 Adaptor technology to achieve non-genotoxic, long-lasting silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and has potential applications in cancer treatment, allowing healthcare providers to offer new therapeutic options for various cancer types. Through its advancements, Ceptur aims to improve patient outcomes by providing effective solutions for difficult-to-treat conditions.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. It specializes in the research, development, and commercialization of novel therapeutic candidates primarily in the field of cancer immunotherapy. The company's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT, both designed for the treatment of solid tumors. Compugen employs advanced computational methods for drug discovery, utilizing in silico techniques to predict and select promising drug targets, followed by rigorous experimental validation. The company collaborates with major pharmaceutical partners, including Bayer Pharma AG and Bristol-Myers Squibb, to enhance its research and development efforts. Compugen's focus on innovative therapeutic solutions aims to address significant unmet medical needs in oncology, leveraging its unique predictive capabilities and a robust pipeline of early-stage programs targeting immune resistance mechanisms.

Clade Therapeutics is a biopharmaceutical company established in 2020 and based in Cambridge, Massachusetts. The company specializes in the discovery and development of scalable, off-the-shelf stem cell-based medicines aimed at treating a variety of diseases, including cancer and autoimmune disorders. Clade Therapeutics integrates advancements in stem cell biology, immunology, regenerative medicine, and gene editing to create next-generation cell therapies. Its initial focus centers on developing therapies utilizing T cells and other immune cells, thereby enhancing the accessibility and effectiveness of stem cell-derived treatments for patients.

Nitrase Therapeutics is a biopharmaceutical company focused on developing innovative therapies targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create treatments that may slow or halt the progression of this condition. The company leverages its proprietary platform, which is based on the biochemical modification of proteins through nitration, to identify nitro-substrates and their relevance in various diseases. This approach not only addresses Parkinson's but also positions Nitrase to expand its research into other therapeutic indications, with the goal of offering novel medicines that target this specific enzyme pathway.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. The company specializes in scalable stem cell cultivation using bioreactors for cGMP cell therapy manufacturing. Its proprietary technology platform, known as C-Stem, offers an end-to-end 3D scalable solution aimed at enhancing cell production and quality. By addressing critical manufacturing challenges, TreeFrog Therapeutics seeks to accelerate clinical development and improve market access for cell therapies, ultimately reducing treatment costs and expanding patient access to innovative medical solutions.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

IMIDomics is a specialized company focused on addressing Immune-Mediated Inflammatory Diseases (IMIDs). It operates by leveraging the world's largest biobank dedicated to IMIDs, alongside its extensive clinical expertise and advanced genomic analysis capabilities. The company develops an analytical platform that provides healthcare professionals with accessible insights from vast amounts of molecular and clinical data, facilitating optimized treatment strategies for patients with IMIDs. With locations at Vall d'Hebron Hospital in Barcelona, Spain, and the HudsonAlpha Institute in Huntsville, Alabama, IMIDomics aims to advance the understanding and management of these complex diseases through innovative biomarker discovery and application.

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.

Aktis Oncology is a biotechnology company focused on the discovery and development of a new class of targeted radiopharmaceuticals aimed at treating various solid tumor cancers. The company has developed proprietary platforms to create tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered for high tumor penetration and prolonged residence time, allowing for effective tumor elimination while reducing the side effects typically associated with cancer treatments. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing treatment precision and efficacy.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, that focuses on enhancing drug development and clinical trials through innovative technology. Founded in 2008, the company has developed the CIVO arrayed microinjection platform, which allows for the simultaneous assessment of multiple drugs or drug combinations directly within a patient's tumor. This method provides insights into drug efficacy, resistance, and potential synergies in the tumor's native microenvironment, thereby overcoming limitations associated with systemic drug administration. By using this clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, ultimately streamlining the development of effective cancer treatments. The technology also facilitates the identification of drug targets and effective combinations, allowing for more accurate measurement of therapeutic responses.

Orna Therapeutics, founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, is a biotechnology company specializing in the development of fully engineered circular RNA therapeutics. The company's proprietary platform combines innovative technology to create circular RNAs that drive protein expression, coupled with validated delivery solutions. This approach aims to simplify production, enhance formula stability, and improve protein expression for treating various diseases.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California, specializing in the discovery, development, and commercialization of targeted therapies for rare cardiovascular diseases. Founded in 2012, the company focuses on heritable cardiomyopathies and genetically-driven heart failure stemming from biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently undergoing Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, which has completed Phase I and IIa trials for dilated cardiomyopathy, alongside several preclinical programs targeting related cardiovascular conditions. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Forbius, also known as Formation Biologics, is a clinical-stage biopharmaceutical company focused on designing and developing innovative therapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, the company specializes in creating agents that target critical biological pathways, specifically the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. By leveraging advanced protein engineering technologies and a deep understanding of biology, Forbius aims to produce highly effective inhibitors with unique mechanisms of action, ultimately striving to improve patient outcomes and transform lives.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Founded in 2017 and originally named Llama Therapeutics, the company aims to address significant unmet medical needs in neuropsychiatry, neurodegeneration, and neuroinflammation. Autobahn's lead candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential adjunctive treatment for multiple sclerosis, adrenomyeloneuropathy, major depressive disorder, and bipolar disorder depression. The company employs a brain-targeting chemistry platform that allows for precise tuning of CNS exposure while pursuing validated clinical and biological targets, guided by biomarkers, to unlock new therapeutic opportunities.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Celgene Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and immune-inflammatory diseases. The company aims to provide treatment options for patients with limited alternatives, conducting numerous clinical trials at major medical centers for its investigational compounds. Celgene's research primarily targets incurable hematological cancers, such as multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma, as well as solid tumors like pancreatic cancer and melanoma. Additionally, the company is developing therapies for serious inflammatory conditions, including psoriasis and psoriatic arthritis. With a commitment to improving patient outcomes, Celgene continues to advance its pipeline of biopharmaceutical drugs.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Celgene Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and immune-inflammatory diseases. The company aims to provide treatment options for patients with limited alternatives, conducting numerous clinical trials at major medical centers for its investigational compounds. Celgene's research primarily targets incurable hematological cancers, such as multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma, as well as solid tumors like pancreatic cancer and melanoma. Additionally, the company is developing therapies for serious inflammatory conditions, including psoriasis and psoriatic arthritis. With a commitment to improving patient outcomes, Celgene continues to advance its pipeline of biopharmaceutical drugs.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Galecto is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to address severe diseases, particularly fibrosis and cancer. Established in 2011, Galecto builds on over a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company's lead product candidate, GB0139, is an inhaled galectin-3 inhibitor specifically designed for treating severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet medical need. Additionally, Galecto is advancing GB1211, an oral selective galectin-3 inhibitor aimed at addressing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto leverages its unique therapeutic platform to target the underlying biological processes associated with fibrosis and related diseases.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. It specializes in the research, development, and commercialization of novel therapeutic candidates primarily in the field of cancer immunotherapy. The company's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT, both designed for the treatment of solid tumors. Compugen employs advanced computational methods for drug discovery, utilizing in silico techniques to predict and select promising drug targets, followed by rigorous experimental validation. The company collaborates with major pharmaceutical partners, including Bayer Pharma AG and Bristol-Myers Squibb, to enhance its research and development efforts. Compugen's focus on innovative therapeutic solutions aims to address significant unmet medical needs in oncology, leveraging its unique predictive capabilities and a robust pipeline of early-stage programs targeting immune resistance mechanisms.

Avera PACE, a division of Avera Health, operates as a regional group-purchasing organization primarily serving clients in the upper Midwest but extending its services across the United States. The organization focuses on providing access to cost-effective contracts, services, and products, benefiting businesses located in both metropolitan and rural areas. By promoting collaboration, utilization, and continuous improvement, Avera PACE helps its clients achieve lower operational costs. Additionally, Avera Medical Group, part of Avera Health, offers a wide range of healthcare services including behavioral health, cancer care, cardiology, pediatrics, emergency care, surgery, neuroscience, and women's health, further enhancing the value and support available to the communities it serves.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Jefferson Health System is a healthcare organization that focuses on delivering high-quality medical services to its patients. The system operates a network of hospitals, outpatient centers, and physician practices in the Philadelphia area. With a commitment to providing patient-centered care, Jefferson Health System offers a wide range of medical specialties and services to meet the diverse needs of its community. Through collaboration with healthcare professionals and cutting-edge research, the organization strives to improve the health and well-being of individuals in the region. Jefferson Health System aims to be a leader in the healthcare industry by maintaining a strong reputation for excellence in patient care and innovation.

Akamis Bio is a clinical-stage oncology company dedicated to advancing cancer treatment through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops a portfolio of therapeutics specifically targeting solid tumors, aiming to enhance patients' immune responses to recognize and eradicate cancer cells. By harnessing a proprietary intravenously administered viral platform, Akamis Bio focuses on delivering effective gene therapies that address the needs of cancer patients, striving to improve their quality of life and treatment outcomes.

The UNC Center for Aging and Health, part of the University of North Carolina School of Medicine, focuses on enhancing the health and well-being of older adults through high-quality clinical care and comprehensive community support. The center connects families and caregivers with essential resources while also addressing the educational needs of future healthcare providers. It trains not only geriatricians but also a variety of specialists, including dentists, pharmacists, cardiologists, and oncologists, in best practices for geriatric medicine. The center emphasizes research-driven approaches that prioritize patient needs and foster compassionate care, thereby ensuring that all healthcare professionals are equipped to meet the complexities of aging populations. Through its commitment to education, quality care, and community engagement, the UNC Center for Aging and Health plays a vital role in improving the overall health of older adults in North Carolina and beyond.

IFM Therapeutics is a biotechnology company focused on developing small molecule medicines that target the innate immune system. It collaborates with academic institutions to leverage expertise in innate immunity alongside experienced drug discovery professionals. The company's subsidiary, IFM Due, specializes in discovering and developing antagonists of the cGAS/STING pathway, aiming to treat conditions such as inflammation, neuroinflammation, autoimmunity, and cancer. Additionally, IFM Discovery operates as an incubator within the company, working on genetically validated targets to create next-generation therapies for similar health challenges. Through its innovative approaches, IFM Therapeutics seeks to enhance immunotherapy and provide solutions for patients with serious diseases.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Cormorant Pharmaceuticals is a privately held biopharmaceutical company located at the Karolinska Institute Science Park in Stockholm, Sweden. Founded by Maarten de Château and Urban Paulsson, the company specializes in the development of therapeutics for cancer and other rare diseases. Cormorant has focused its efforts on HuMax-IL8, a fully human monoclonal antibody acquired from Genmab A/S. This drug is based on research indicating that interleukin-8 (IL-8) plays a significant role in the progression of malignant tumors. Through its innovative approach, Cormorant Pharmaceuticals aims to address critical unmet medical needs in oncology and rare disease treatment.

Blade Therapeutics is a discovery-stage drug development company focused on creating antifibrotic treatment strategies for a range of congenital and acquired fibrotic diseases. The company aims to revolutionize the treatment of these conditions by addressing their underlying pathophysiology, potentially reversing tissue damage caused by fibrosis. With a leadership team experienced in drug development for fibrotic disorders, Blade Therapeutics collaborates with international experts to identify and in-license innovative technologies, thereby building a robust pipeline of antifibrotic compounds. Their therapies are designed to offer effective treatment options that minimize side effects for patients suffering from fibrotic diseases.

Padlock Therapeutics is a biotechnology company focused on developing innovative medicines that target protein-arginine deiminases (PADs), which are enzymes involved in the generation of autoantigens and play a significant role in inflammation and immune responses associated with autoimmune diseases. The company aims to investigate the biological and therapeutic implications of protein deimination by PADs. Founded by scientists from The Scripps Research Institute in collaboration with members of the Atlas Venture Life Sciences Team, Padlock operates as a seed-stage company based in Cambridge, Massachusetts. Its investors include prominent names such as Atlas Venture, Johnson & Johnson, and MS Ventures.

Cardioxyl Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease. The company is dedicated to discovering, developing, and commercializing novel technologies in areas where existing treatments are lacking or inadequate. With a strong emphasis on nitroxyl technology, Cardioxyl has established significant expertise in its chemistry, biology, and clinical applications. The company's leading candidate, CXL-1020, is currently undergoing clinical development for Acute Decompensated Heart Failure, a condition that is a primary cause of hospitalization among patients over the age of 65. Through its research and development efforts, Cardioxyl aims to address critical unmet needs in cardiovascular care.

Flexus Biosciences, established in 2013 and based in San Carlos, California, is a privately-held biopharmaceutical company dedicated to developing innovative small-molecule cancer therapeutics. Its primary focus lies in targeting regulatory T cells, aiming to create novel immunotherapies that enhance the body's immune response against cancer.

iPierian is a biotechnology company specializing in the development of therapies for neurodegenerative diseases. Utilizing induced pluripotent stem cells, the company focuses on addressing significant unmet medical needs, particularly in conditions such as spinal muscular atrophy, amyotrophic lateral sclerosis, and Parkinson's disease. iPierian is engaged in the research and development of innovative therapies, including monoclonal antibodies aimed at treating Alzheimer's disease and other Tauopathies. By targeting the mechanisms that drive disease progression, the company aims to provide physicians with effective tools to slow the spread of Tau in the brain, thereby potentially improving patient outcomes.

Amylin Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs aimed at treating diabetes, obesity, and other related diseases. The company is known for its flagship product, BYDUREON, a weekly treatment designed for adults with type 2 diabetes to enhance glycemic control in conjunction with diet and exercise. Amylin has also developed a dual chamber cartridge pen configuration for BYDUREON, enabling patients to mix and administer the medication conveniently from a pre-filled pen device. With a commitment to advancing diabetes care, Amylin Pharmaceuticals aims to challenge scientific boundaries and improve the lives of individuals affected by these conditions.

Inhibitex is a biotechnology company that specializes in the development of antibody-based products aimed at preventing and treating bacterial and fungal infections. The company is particularly focused on creating small molecule antiviral compounds, with specific attention to therapies for shingles, also known as herpes zoster, and chronic hepatitis C infections. Through its innovative approach, Inhibitex seeks to address significant medical needs in the realm of infectious diseases.

Amira Pharmaceuticals is a small molecule pharmaceutical company dedicated to the discovery and early development of innovative drugs for treating inflammatory diseases. The company leverages its team’s expertise in bioactive lipid pathways and complex signaling processes to address various conditions, including asthma, chronic obstructive pulmonary disease, cardiovascular diseases, and fibrotic diseases. Through its focused research efforts, Amira Pharmaceuticals aims to create effective therapeutic solutions that can significantly improve patient outcomes in these areas.

ZymoGenetics is a biotechnology company dedicated to the discovery, development, and early manufacturing of therapeutic proteins aimed at treating human diseases. As a fully-integrated research and development organization, it possesses a diverse array of competencies, including molecular and cellular biology, protein chemistry, and antibody generation and engineering. The company is actively involved in the clinical development and operations of its products and addresses regulatory affairs and quality control. ZymoGenetics is known for its therapeutic pipeline, which includes recothrom, a protein designed for hemostasis, underscoring its commitment to advancing innovative treatments in the biopharmaceutical sector.

CareDx, Inc. is a precision medicine company that specializes in developing and commercializing innovative healthcare solutions for transplant patients and their caregivers. The company offers a range of molecular diagnostics products, including AlloSure Kidney and AlloMap Heart, which utilize donor-derived cell-free DNA to assess organ transplant health and identify potential rejections noninvasively. CareDx also provides various solutions for human leukocyte antigen typing, chimerism testing, and post-transplant monitoring. Its offerings extend to patient tracking software and predictive analysis tools, enhancing the overall transplant experience from initial matching to ongoing care. Founded in 1998 and headquartered in South San Francisco, California, CareDx has established partnerships for the development and distribution of advanced genomic testing technologies, further solidifying its role as a leader in transplant diagnostics.

Medarex is a biopharmaceutical company dedicated to the discovery, development, and potential commercialization of fully human antibody-based therapeutics aimed at treating life-threatening and debilitating diseases, such as cancer, inflammation, autoimmune disorders, and infectious diseases. The company leverages its UltiMAb technology, along with its expertise in product development and clinical manufacturing, to create and support a diverse range of fully human antibody product candidates. Medarex focuses on advancing these therapeutics for both its own portfolio and in collaboration with partners in the biopharmaceutical industry.